Heparin Scare Drives Call For API Sources On Drug Labels
This article was originally published in PharmAsia News
Some physicians and consumers in the United States are urging the FDA to require drug labeling that discloses the origins of the product. The reaction is in response to announcements of deaths that may be connected with heparin blood-thinner made from imported ingredients from China. The pro-labeling groups note that fruits and other commodities are labeled by source, while even a look on drug Web sites usually does not identify the source of drug ingredients, either active or inactive. The FDA requires the name and address only of the manufacturer, packer or distributor, but not the API source, which is treated as confidential. Drug makers say good manufacturing practice requirements, if followed, handle those concerns. (Click here for more - a subscription may be required
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.